Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
You can paste this link into an email or message to share this resource with your patient.
Acute lymphoblastic leukaemia (ALL) is an aggressive haematologic malignancy characterised by the uncontrolled proliferation of immature lymphoid cells in the bone marrow and peripheral blood. Rapid diagnosis and intervention are critical to improve outcomes. ALL remains a critical focus in haematology, with evolving molecular insights and advances in risk stratification driving precision treatment strategies, ultimately leading to enhanced patient outcomes.
AmgenPro is intended for healthcare professionals in Australia
Login or create an AmgenPro account to access the latest updates on our products, medical resources and patient programs.
AUS-103-26-80037 | May 2026